PMID- 36584198 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230114 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 12 DP - 2022 TI - Clinical features and outcomes of breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy. PG - e0279778 LID - 10.1371/journal.pone.0279778 [doi] LID - e0279778 AB - Polypoidal choroidal vasculopathy (PCV) with hemorrhagic complications is at higher risk for breakthrough vitreous hemorrhage (VH). This study aimed to evaluate the clinical features and outcomes of breakthrough VH secondary to PCV. Data of patients receiving pars plana vitrectomy for breakthrough VH secondary to PCV (VH group) were evaluated retrospectively and compared statistically to data of age and sex-matched PCV patients without breakthrough VH (control group). Among PCV patients, 36 eyes with breakthrough VH and 62 eyes without VH were included. Compared with baseline, best corrected visual acuity (BCVA) was worse in the VH group (P < 0.001), and improved postoperatively (P < 0.001). Percentages of pigmented epithelial detachment (PED), hemorrhagic PED, massive subretinal hemorrhage, hemorrhagic retinal detachment (RD), and hemorrhagic choroidal detachment (CD) (P = 0.007) were higher in the VH group (P < 0.001). Incidence of choroidal vascular hyperpermeability (P < 0.001), massive subretinal hemorrhage (P = 0.001), hemorrhagic retinal detachment (P = 0.001) and hemorrhagic type PCV (P = 0.001) was higher in patients with pachychoroid PCV, while fibrovascular type had lower incidence (P < 0.001). Better initial BCVA (P < 0.001), higher frequency of anti-VEGF treatment (P = 0.009), and previous photodynamic therapy (P = 0.017) showed better visual outcomes. Breakthrough VH risk is higher in PCV patients with massive subretinal hemorrhage, hemorrhagic PED and hemorrhagic RD. BCVA and hemorrhagic complications improve significantly postoperatively. Higher frequency of anti-VEGF treatment and previous photodynamic therapy are associated with better visual prognosis in PCV patients with breakthrough VH. CI - Copyright: (c) 2022 Li, Tsen. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Li, Meng-Syuan AU - Li MS AUID- ORCID: 0000-0002-6550-5064 AD - Division of Ophthalmology, Pingtung Veterans General Hospital, Pingtung, Taiwan, R.O.C. AD - Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C. FAU - Tsen, Chui-Lien AU - Tsen CL AUID- ORCID: 0000-0002-4997-3562 AD - Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C. AD - Department of Optometry, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan, R.O.C. LA - eng PT - Journal Article DEP - 20221230 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Angiogenesis Inhibitors) SB - IM MH - Humans MH - *Vitreous Hemorrhage/etiology/surgery MH - Polypoidal Choroidal Vasculopathy MH - Angiogenesis Inhibitors/therapeutic use MH - *Retinal Detachment/surgery/complications MH - Retrospective Studies MH - Retinal Hemorrhage/surgery/complications MH - Choroid/blood supply MH - Fluorescein Angiography MH - Tomography, Optical Coherence PMC - PMC9803236 COIS- The authors declare no competing interests. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 PMCR- 2022/12/30 CRDT- 2022/12/30 14:06 PHST- 2022/09/25 00:00 [received] PHST- 2022/12/14 00:00 [accepted] PHST- 2022/12/30 14:06 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - PONE-D-22-26561 [pii] AID - 10.1371/journal.pone.0279778 [doi] PST - epublish SO - PLoS One. 2022 Dec 30;17(12):e0279778. doi: 10.1371/journal.pone.0279778. eCollection 2022.